Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN1A | P35498 | 15/20 | 0.39 |
| ▸ | SCN8A | Q9UQD0 | 15/20 | 0.39 |
| ▸ | SCN5A | Q14524 | 10/20 | 0.37 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.35 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | IDH2 | P48735 | 1/20 | 0.33 |
| ▸ | ACLY | P53396 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19968815 | 1.00 | SCN1A (0.39) | SCN1ASCN8ASCN5ASLC40A1NTRK1 | |
| SCHEMBL22323213 | 0.91 | SCN1A (0.41) | SCN1ASCN8ASCN5ASLC40A1SCN9A | |
| SCHEMBL24360868 | 0.86 | SCN1A (0.39) | SCN1ASCN8ASCN5ASLC40A1SCN9A | |
| SCHEMBL19927705 | 0.84 | SCN1A (0.38) | SCN1ASCN8ASCN5ASLC40A1 | |
| SCHEMBL29464874 | 0.84 | SCN1A (0.38) | SCN1ASCN8ASCN5ASLC40A1 | |
| SCHEMBL22323186 | 0.84 | SCN1A (0.37) | SCN1ASCN8ASCN5ASLC40A1SCN9A | |
| SCHEMBL22323258 | 0.83 | SCN1A (0.38) | SCN1ASCN8ASCN5ASLC40A1SCN9A | |
| SCHEMBL22117239 | 0.82 | SCN1A (0.38) | SCN1ASCN8ASCN5ASCN9A | |
| SCHEMBL22323203 | 0.82 | SLC40A1 (0.40) | SCN1ASCN8ASCN5ASLC40A1NTRK1 | |
| SCHEMBL22117204 | 0.82 | SLC40A1 (0.41) | SCN1ASCN8ASCN5ASLC40A1SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109641873-B | N- (pyridin-2-yl) pyridine-sulfonamide derivatives and their use for the treatment of disease | 诺华股份有限公司 | 2022-03-18 | — | — | CN | disclosed |